FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046398619> ?p ?o ?g. }

• W2046398619 endingPage "180" @default.
• W2046398619 startingPage "177" @default.
• W2046398619 abstract "Oral cephalexin, 1 to 2 g daily for 3 days, was given to six stable, noninfected patients receiving maintenance continuous ambulatory peritoneal dialysis (CAPD). The peak serum concentration after a 2 g initial dose was between 73 and 123 mg/L. On the second and third day in five patients who received a 2 g daily oral dose, the serum concentrations were between 35 and 118 mg/L in serum obtained 1 to 1.5 hours after the dosing. Similar serum concentrations were seen in one patient who only received a 1 g oral dose on the second and third day. Cephalexin concentrations in the peritoneal dialysate reached a peak on the first day between 4 to 14 hours after the dose and were between 31 to 78 mg/L. During the second and third day, the highest cephalexin concentration was 118 mg/L and the lowest was 12 mg/L. The data are consistent with the feasibility of oral cephalexin for treatment of CAPD-associated peritonitis with microorganisms that are sensitive to these levels of cephalexin. Oral cephalexin, 1 to 2 g daily for 3 days, was given to six stable, noninfected patients receiving maintenance continuous ambulatory peritoneal dialysis (CAPD). The peak serum concentration after a 2 g initial dose was between 73 and 123 mg/L. On the second and third day in five patients who received a 2 g daily oral dose, the serum concentrations were between 35 and 118 mg/L in serum obtained 1 to 1.5 hours after the dosing. Similar serum concentrations were seen in one patient who only received a 1 g oral dose on the second and third day. Cephalexin concentrations in the peritoneal dialysate reached a peak on the first day between 4 to 14 hours after the dose and were between 31 to 78 mg/L. During the second and third day, the highest cephalexin concentration was 118 mg/L and the lowest was 12 mg/L. The data are consistent with the feasibility of oral cephalexin for treatment of CAPD-associated peritonitis with microorganisms that are sensitive to these levels of cephalexin." @default.
• W2046398619 created "2016-06-24" @default.
• W2046398619 creator A5005563916 @default.
• W2046398619 creator A5027161458 @default.
• W2046398619 creator A5083165884 @default.
• W2046398619 date "1985-09-01" @default.
• W2046398619 modified "2023-09-23" @default.
• W2046398619 title "Serum and Dialysate Concentrations of Cephalexin Following Repeated Dosing in CAPD Patients" @default.
• W2046398619 cites W1549438343 @default.
• W2046398619 cites W1930375491 @default.
• W2046398619 cites W1997463118 @default.
• W2046398619 cites W2003033685 @default.
• W2046398619 cites W2007960939 @default.
• W2046398619 cites W2020048304 @default.
• W2046398619 cites W2086311253 @default.
• W2046398619 cites W2088465257 @default.
• W2046398619 cites W2114527565 @default.
• W2046398619 cites W2397394063 @default.
• W2046398619 cites W2416998173 @default.
• W2046398619 doi "https://doi.org/10.1016/s0272-6386(85)80023-8" @default.
• W2046398619 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/4036960" @default.
• W2046398619 hasPublicationYear "1985" @default.
• W2046398619 type Work @default.
• W2046398619 sameAs 2046398619 @default.
• W2046398619 citedByCount "4" @default.
• W2046398619 crossrefType "journal-article" @default.
• W2046398619 hasAuthorship W2046398619A5005563916 @default.
• W2046398619 hasAuthorship W2046398619A5027161458 @default.
• W2046398619 hasAuthorship W2046398619A5083165884 @default.
• W2046398619 hasConcept C112705442 @default.
• W2046398619 hasConcept C126322002 @default.
• W2046398619 hasConcept C2777056448 @default.
• W2046398619 hasConcept C2777288759 @default.
• W2046398619 hasConcept C2779056158 @default.
• W2046398619 hasConcept C2779978075 @default.
• W2046398619 hasConcept C2780199535 @default.
• W2046398619 hasConcept C2909406889 @default.
• W2046398619 hasConcept C35785553 @default.
• W2046398619 hasConcept C71924100 @default.
• W2046398619 hasConcept C90924648 @default.
• W2046398619 hasConceptScore W2046398619C112705442 @default.
• W2046398619 hasConceptScore W2046398619C126322002 @default.
• W2046398619 hasConceptScore W2046398619C2777056448 @default.
• W2046398619 hasConceptScore W2046398619C2777288759 @default.
• W2046398619 hasConceptScore W2046398619C2779056158 @default.
• W2046398619 hasConceptScore W2046398619C2779978075 @default.
• W2046398619 hasConceptScore W2046398619C2780199535 @default.
• W2046398619 hasConceptScore W2046398619C2909406889 @default.
• W2046398619 hasConceptScore W2046398619C35785553 @default.
• W2046398619 hasConceptScore W2046398619C71924100 @default.
• W2046398619 hasConceptScore W2046398619C90924648 @default.
• W2046398619 hasIssue "3" @default.
• W2046398619 hasLocation W20463986191 @default.
• W2046398619 hasLocation W20463986192 @default.
• W2046398619 hasOpenAccess W2046398619 @default.
• W2046398619 hasPrimaryLocation W20463986191 @default.
• W2046398619 hasRelatedWork W1996044071 @default.
• W2046398619 hasRelatedWork W2017197437 @default.
• W2046398619 hasRelatedWork W2032351422 @default.
• W2046398619 hasRelatedWork W2115620887 @default.
• W2046398619 hasRelatedWork W2317811571 @default.
• W2046398619 hasRelatedWork W2337380521 @default.
• W2046398619 hasRelatedWork W2468009384 @default.
• W2046398619 hasRelatedWork W2469565985 @default.
• W2046398619 hasRelatedWork W2472224673 @default.
• W2046398619 hasRelatedWork W2725317505 @default.
• W2046398619 hasVolume "6" @default.
• W2046398619 isParatext "false" @default.
• W2046398619 isRetracted "false" @default.
• W2046398619 magId "2046398619" @default.
• W2046398619 workType "article" @default.